Spyre Therapeutics, Inc.
SYRE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $65 | $82 | $48 | $89 |
| Short-Term Investments | $421 | $445 | $516 | $514 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $18 | $12 | $5 | $5 |
| Total Curr. Assets | $505 | $539 | $570 | $608 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $505 | $539 | $570 | $608 |
| Liabilities | – | – | – | – |
| Payables | $7 | $4 | $4 | $1 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $39 | $79 | $67 | $53 |
| Total Curr. Liab. | $46 | $83 | $71 | $54 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $3 | $0 | $16 | $37 |
| Total NC Liab. | $3 | $0 | $16 | $37 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $50 | $83 | $87 | $91 |
| Equity | – | – | – | – |
| Pref Stock | $156 | $156 | $156 | $156 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,065 | -$1,054 | -$1,017 | -$972 |
| AOCI | $1 | $0 | $1 | $0 |
| Other Equity | $1,364 | $1,353 | $1,343 | $1,334 |
| Total Equity | $455 | $456 | $483 | $518 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $505 | $539 | $570 | $608 |
| Net Debt | -$65 | -$82 | -$48 | -$89 |